1. Balis FM, Lester CM, Poplack DG (1986) Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 46: 169
2. Bertino JR, Sawicki WK, Moroson BA, Cashmore AR (1979) 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxcyanilino)methyl] quinazoline (TMQ), a potent non-classical folate antagonist: I. Effect on dihydrofolate reductase and growth of rodent tumor in vitro and in vivo. Biochem Pharmacol 28: 1983
3. Bertino JR, Sobrero A, Mini E, Moroson BA, Cashmore A (1987) Design and rationale for novel antifolates. NCI Monogr 5: 87
4. Chabner B (1982) Pharmacologic principles of cancer treatment. W. B. Saunders, Philadelphia, p 236
5. Diddens H, Niethammer D, Jackson R (1983) Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43: 5286